Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.52 |
| ▸ | METAP1 | P53582 | 3/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | ACP1 | P24666 | 2/20 | 0.48 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.48 |
| ▸ | GPR39 | O43194 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3785925 | 0.84 | HTR3A (0.49) | CYP3A4METAP1KDM4EACP1TGFBR1 | |
| SCHEMBL8646097 | 0.81 | CYP2C9 (0.52) | CYP3A4METAP1CYP2C9MAPK1KDM4E | |
| SCHEMBL12090552 | 0.80 | TGFBR1 (0.70) | CYP3A4METAP1CYP2C9KDM4ERXFP1 | |
| SCHEMBL15692161 | 0.79 | MAPK1 (0.56) | CYP3A4METAP1CYP2C9MAPK1KDM4E | |
| SCHEMBL13243235 | 0.76 | CYP3A4 (0.53) | CYP3A4METAP1CYP2C9MAPK1KDM4E | |
| SCHEMBL25416501 | 0.76 | KDM4E (0.61) | CYP3A4METAP1CYP2C9MAPK1KDM4E | |
| SCHEMBL10610977 | 0.76 | KDM4E (0.57) | CYP3A4METAP1CYP2C9MAPK1KDM4E | |
| SCHEMBL2712210 | 0.76 | ACHE (0.64) | CYP3A4METAP1CYP2C9KDM4ERXFP1 | |
| SCHEMBL30368831 | 0.76 | ACHE (0.64) | CYP3A4METAP1CYP2C9KDM4ERXFP1 | |
| SCHEMBL31529370 | 0.75 | SMN1; SMN2 (0.67) | CYP3A4METAP1CYP2C9KDM4ERXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940724-B2 | Quinoline derivitives and their uses | AMGEN INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-20100331293-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331293-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | CYP3A4 3011/4885METAP1 4171/4885CYP2C9 3078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.